The oral route is most familiar route as it has low cost of therapy and helps in the ease of administration of therapeutic agents which lead to high levels of patient compliance. The most known oral solid dosage forms are tablets and capsules. Many patients' particularly pediatric and geriatric patients find it difficult to swallow tablets and hard gelatin capsules and do not take their medicines as prescribed. Difficulty in swallowing or dysphagia is identified to afflict nearly 35% of the general population. To reduce these difficulties, the growth of several fast dissolving drug delivery systems has been produced. Oral dissolving film is relatively a new dosage form in which thin film is prepared using hydrophilic polymers, which rapidly dissolves on tongue or buccal cavity. The film overcomes the danger/fear of choking. An ideal film should have the characteristics like pleasant taste, high stability, ease of handling and administration, no water necessary for administration. The present review focuses on hydrophilic polymers, plasticizers, sweeteners, flavors and colors etc which are used in the formulation of oral dissolving films including the manufacturing aspects of oral dissolving film like solvent casting method, rolling method, extrusion method and solid dispersion method and evaluation parameters like disintegration, dissolution, tensile strength, thickness, folding endurance, elastic modulus for oral dissolving films.
INTRODUCTION
In solid dosage forms, some patients have major problem in the use of tablets was swallowing or chewing which forms risk or fear of chocking. In the oral delivery of drug, oral dissolving film is a new drug delivery system. Oral film a type of film which is utilized in severe condition such as pain, antiemetic, anti-migraine, anti-hypertension, congestive heart failure, and Asthma etc. Oral dissolving film has attained popularity due to its availability in various size and shape 1 . Oral dissolving films are meant to disintegrate or dissolve within seconds. They provide advantages like administration without water, rapid onset of action and convenience of dosing. For fast dissolving dosage forms, active pharmaceutical ingredients absorption is feasible through the oral mucosa and may improve bioavailability 2 .
II. The concept of oral dissolving film (ODF)
 This delivery system composed of a thin film.  After keeping it on the top of the tongue, the film dissolves within seconds, promoting first pass metabolism as estimated to tablet and other immediate release oral solid dosage forms, and may enhance the bioavailability of drug 3 .
 ODF dissolves in the mouth like a cotton candy.
III. The benefits of oral dissolving film (ODF) when compared with fast dissolving film (FDT)
 Accessibility of larger surface area that drives to faster disintegration and dissolution in the oral cavity within seconds 4 .
 During transportation and storing of ODF, they don't need any kind of special protection as they are flexible when compared with fast dissolving tablets as they are fragile.
 Among dysphasic patients, negative requirement of water had led to satisfactory results for ODF.
 Usage of ODF gives no fear of chocking when compared with fast dissolving tablets.
 The considerable surface area present in the film dosage form gives rapid wetting by saliva and quickly disintegrates which dissolve and absorbed directly and can enter the systemic circulation without undergoing first-pass hepatic metabolism and on enhancement the bioavailability 5 .
 As per convenience of the individual, the dosage form can be consumed at any place and any time.
 The first pass effect can be ignored, so a decrease in the dose which can guide to reduction in side effects associated with the molecule 6 .
 Patients suffering from dysphagia, repeated emesis, hypertension, heart attack, asthma, motion sickness, paralysis and mental disorders favor this dosage form as they are not capable to swallow large quantities of water.
IV. Formulation of oral dissolving films:
The oral dissolving films composition is given in table 1. o It must not aid in cause secondary infections in the oral mucosa/ dental region. o It must have a good mouth feel property. o Polymer employed must be non-toxic, non-irritant and devoid of leach able impurities.
C. Plasticizers
It is an essential ingredient in oral film as it imparts flexibility to the film by reducing its brittleness and improves the strip property for preparing the oral film. It also improves the flow of polymer and enhances the strength of the polymer. The selection of plasticizer will rely upon its compatibility with the polymer and also solvent employed in the casting of the strip. Plasticizers are frequently used in the concentration of 0-20%w/w of dry polymer weight.
D. Strip Forming Polymers
The polymers in the formulation can be used alone are in combination to obtain the desired strip properties. The film obtained should be tough enough so that they won't be any damage while handling or during transportation. The robustness of the strip will rely upon the type of polymer and its amount. A variety of polymers are available for the preparation of oral strip. On the other side, fast dissolving strip dosage form must have the ability to disintegrate in seconds when placed in mouth and deliver the drug to the oral cavity instantaneously. Various polymers used in the formulation of oral strips are given in table 2 .Of the various polymers available pullulan, gelatin and hydromellose are most commonly used for preparation of oral strip. Atleast 45% w/w of polymers should generally be present based on the total weight of dry oral strip. 
E. Saliva Stimulating Agent
A saliva stimulating agent is utilized to enhance the rate of production of saliva, because the saliva helps in rapid disintegration of fast dissolving film formation. Saliva stimulating agents are utilized alone as well as in combination between 2 to 6% w/w of the weight of the film 9 .
F. Sweetening Agent
This is the most essential part of the food product or in pharmaceutical dosage forms. Natural as well as artificial sweetening agents are utilized to improve the palatability of the formulation. Sweetening agents commonly used either alone or in combination between the concentrations of 3 to 6%w/w 10 .
G. Flavoring Agent
Selection of flavor depends on which type of drug is to be administered in the formulation. The perception of the oral disintegrating / dissolving formulation by an individual, depends on the initial flavor quality which is noticed in the first few seconds after the product has been absorbed and the after taste of the formulation which lasts for at least about 10 min. Preferable concentration of flavor 10%w/w 11, 12, 13 .
H. Surfactant
Surfactants are utilized as a solubilising or wetting dispersing agent so that the film dissolves within seconds and release the active agent immediately.
I. Coloring Agent
FDA approved coloring agents are used in the manufacturing of oral dissolving films. (Not exceeding concentration levels of 1%w/w). For example: titanium dioxide. 
B. Semisolid Casting
In this method a solution of water soluble film forming polymer should be prepared and the resulting solution should be added to a solution of acid insoluble polymer (e.g. cellulose acetate phthalate, cellulose acetate butyrate), which was made in ammonium or sodium hydroxide. Then suitable amount of plasticizer should be added to form a gel mass. Finally, the gel mass should be casted in to the films or ribbons using heat controlled drums. The thickness of the film formed will be in the rapid of 0.015-0.05 inches. The ratio of the acid insoluble polymer to film forming polymer must be 1:4 in this method.
C. Hot Melt Extrusion (HNE)
In this method, the drug is mixed with carriers in solid form and then the extruder having heaters melts the mixture. Finally the melt is formed in to films by the dies. There are certain benefits of hot melt extrusion 18. o It has a fewer operation units.
o It has better content uniformity.
o It is an anhydrous process.
o Hot melt extrusion process is based on polymer with a high glass transition temperature such as PVP 14 .
The pharmaceutical challenges of API can be overcome by using HME which is given in table 7. The advantages and disadvantages of HME are given in table 8. Advantages Disadvantages Improved bioavailability of poorly soluble compounds.
Thermal process (drug/polymer stability). During processing solvents and water are not required.
Flow properties of the polymer are necessary to processing. Cost-effective process with reduced production time and number of unit operations.
Limited amount of available polymer.
Better content uniformity was obtained among granules of different size ranges.
Require high power input.
The melt technique cannot be applied to heat-sensitive materials due to the evaluated temperatures involved.
D. Solid dispersion extrusion
In this method immiscible components are ejected with drug and then solid dispersions are prepared. Finally the solid dispersions are formed in to films by means of dies.
E. Rolling Method
In rolling method a solution or suspension having drug is rolled on a carrier. The solvent is mainly water and mixture of water along with alcohol. The film is dried on the rollers, cutted in to desired shapes and sizes.
VI. Evaluation of Fast Dissolving Films
A. Thickness: The thickness of film can be determined by micrometer screw gauge at different strategic locations (at least 5 locations). This is important to determine uniformity in the thickness of the film as it is directly related to the accuracy of dose in the film.
B. Dryness Test/Tack Tests: About eight levels of film drying process have been identified and they are set-totouch, dust-free, tack-free (surface dry), Dry-to-touch, dry-hard, dry-through (dry-to-handle), dry-to-recoat and dry print free.
C. Tensile Strength:
Tensile strength is the maximum stress in seconds applicable to a point at which the film specimen breaks 20 . It is measured by the applied load at rupture divided by the cross-sectional area of the film as given below: 
D. Percent Elongation:
When stress is applied, a film sample stretches and this is indicated to as strain. Strain is basically the deformation of film divided by original dimension of the sample. As the elongation of film increases, the plasticizer content increases 21, 22. Where L = Increase in length of film L0 = Initial length of film E. Tear Resistance: The maximum stress or force (that is meter generally found near the onset of tearing) needed to tear the film is noted as the tear resistance value in Newton (or pounds-force).
F. Young's Modulus: Young's modulus or elastic modulus is the measure of stiffness of film. It is determined as the ratio of applied stress over strain in the region of elastic deformation as follows:
Hard and brittle film determines a high tensile strength and Young's modulus with small elongation.
G. Folding Endurance:
Folding endurance is demonstrated by repeated folding of the film at the same place till the film breaks. The number of times the film is folded without breaking is reported as the folding endurance value 23. H. Stickiness Determination: It is determined by texture method usually used for measurement of the tack of pressure sensitive adhesives.
I. Swelling Index 24 :
It is useful in case of film formulation having gelling property and determined by two methods.
J. Linear Expansion Coefficient in Water:
The film (1 x 1 cm 2 ) was placed in a petridish and immersed in 10 ml of distilled water. Specimens were taken at 30, 40, 60, 80, 100, 120, 140, 160 and 180 seconds and the size of the side length was measured. The linear expansion coefficient (L %) was defined as
Where-La = Side length after immersion, Lb = Side length before immersion K. Amount Absorbed: The film is weighed (Wa) and is placed in the stainless steel mesh basket. The weight after immersion in water is determined (Wc).Similarly weight after immersion of basket without film is determined (Wc).The amount absorbed (W) is determined by following equation:
L. Contact Angle Measurement [25] : Time dependent Contact angle is determined by an optical contact angle meter. The contact angle determined by different methods like the two tangential methods, a height width ratio, the circle fitting and sessile drop fitting. It's prediction for wetting behavior, disintegration and dissolution of oral films.
M. Disintegration Time: The disintegration time limit ie: ≤ 30s for orally disintegrating tablets was described in centre for drug evaluation and research (CDER) guidance can be applied to fast dissolving oral film. Although no official guidance is described for oral fast disintegrating films/strips, this may be utilized as a qualitative guideline for quality control test or at development stage. Pharmacopoeial disintegrating test apparatus may be utilized for this study. Typical disintegration time for film is 5-30s.
N. Dissolution Test: Dissolution testing can be operated using the standard basket or paddle apparatus determined in any of the pharmacopoeia. The volume of dissolution medium should be selected as per the sink conditions along with highest dose of the API 26 . Many times the dissolution test can be challenging due to the tendency of the film to float onto the dissolution medium when the paddle apparatus is employed. So mostly we utilize the basket apparatus for evaluation.
O. Dissolution rate via conductivity: Within one minute, the fast dissolving oral films dissolve completely. Currently, mostly of the marketed oral films contain ionisable components. For greater resolution monitoring of the dissolution of fast dissolve oral films, they measure conductivity of the dissolution medium.
P. Assay/Drug content and content uniformity: This is calculated by any standard assay method described for the particular API in any of the standard pharmacopeia. Content uniformity is calculated by estimating the API content in the individual film. The content uniformity limit was in the range of 85-115%.
Q. Organoleptic Evaluation: This is important step in case of most oral formulations due to its more residence time in the oral cavity. The product must possess the desired features of sweetness and flavor which is acceptable to a large mass of population. For evaluation of psychophysical products, special controlled human taste panels are utilized. In-vitro methods of utilizing taste sensors, specially designed apparatus along with drug release by modified pharmacopoeial methods being utilized for this purpose 27 . Experiments utilizing electronic tongue measurements have also been reported to distinguish between the sweetness levels in taste-masking formulation.
R. Morphology Studies [28] : Scanning electron microscopy (SEM) study specifies the differences between upper and lower side of the films. It also helps in demonstration of the distribution of API. Near-infrared chemical imaging (NIR-CI) study helps in demonstrating the difference between drug distributions in drug loaded films and recrystallization.
VII. Technologies to Produce Films
A. Soluleaves™ technology is utilized to produce a range of oral delivery films that can incorporate active ingredients, colours and flavours. Soluleaves™ films can be dissolved rapidly on contact with saliva and instantly releases the active ingredients and flavours. For pharmaceutical uses this method of administration is mainly useful for paediatric or elderly patients who may have difficulty swallowing traditional tablets or capsules. The delivery system can be utilized for the cough/cold, gastrointestinal and pain therapeutic areas as well as delivering nutritional products. Soluleaves™ films can also be designed to attach to mucous B. Wafertab™ is a drug delivery system that administers pharmaceutical actives into an ingestible filmstrip. The system gives rapid dissolution and release of actives when the strip comes into contact with saliva in the mouth. The Wafertab™ filmstrip can be flavoured for furthermore improved taste masking. The active ingredient is accurately dosed and integrated into the body of a pre-manufactured Xgel™ film, thus blocking the exposure to unnecessary heat and moisture and potentially enhancing product stability. The Wafertab™ system accommodates itself for many possibilities of innovative product design, enabling multiple films with different actives to be bonded together. Wafertab™ can be processed in a variety of shapes and sizes and it is an ideal method for delivery of medicines, which needs fast release, or for use by patients who have difficulty in swallowing.
C. Foamburst™ is a distinct variant of the Soluleaves™ technology where an inert gas goes into the film during production. This concludes in a film with a honeycombed structure, which dissolves fastly giving a novel mouth sensation. Foamburst™ has intrigued interest from food and confectionary manufacturers as a means of carrying and releasing flavours.
D. Xgel™ film is at the centre of Meldex International's intellectual property, utilized in all its film systems along with its ingestible dosage delivery technologies. Xgel™ film gives unique product benefits for healthcare and pharmaceutical products, it is non animal-derived, accepted on religious grounds and is applicable for vegetarians; the film is genetically modified organisms (GMO) free and continuous production processing gives an economic and competitive manufacturing platform. Xgel™ film can be taste masked, coloured, layered, and efficient of being enteric properties and also having the ability to administer active pharmaceutical ingredients. The Xgel™ film systems can be manufactured to encapsulate any oral dosage form and also can be solubilized in either cold or hot water. Xgel™ film is contained of a range of different water-soluble polymers, particularly optimised for the intended use.
VIII. Packaging of the Films:
The fast dissolving system can be packaged utilizing various options, such as single pouch, blister card with multiple units, multiple-unit dispenser and continuous roll dispenser. There are some patented packaging systems for oral film given in the table 9. 
IX. Clinical and Regulatory Aspects:
In the US Food and Drug Administration, if the product is bioequivalent to that of the existing oral product of the drug, an Abbreviated New Drug Application (ANDA) route is followed. There are no clinical studies related in this generic approval process (section 505(j) of the Food, Drug and Cosmetics Act). The example of aforementioned case would be a comparative bioequivalence between ODT formulation and OTF product. However, developed oral film product may also display a different target pharmacokinetic profile correlated to the existing marketed product. The OTF is classified as "new dosage form" and the section 505(b)(2) approval process needs to be followed. In this case, a new clinical study would be needed. The benefit of a new clinical study is that it would award three years of marketing exclusivity to the product. In the Europe, Marketing Authorization approval (Abridged Application) is important as per the European Medicines Evaluation Agency guidelines. Either of the two modes i.e. the decentralized procedure or the mutual recognition route can be accepted. The Ministry of Health, Labor and Welfare is primarily answerable for product approvals in Japan. 
